

SARS CoV-2 Spike Glycoprotein South Africa variant Blocking Peptide for STJ506305 peptide (South Africa variant) (STJ506306)

GENERAL INFORMATION	
Product Type	Biomolecules
Applications	Immunodepletion/Immunocompetition
PRODUCT PROPERTIES	
Formulation	Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice.
Storage Instruction	Store at -20°C for long term storage. Avoid freeze-thaw cycles.
TARGET INFORMATION	
Immunogen Region	400-450
Specificity	This blocking peptide is recommended for use in combination with SARS CoV-2 Spike Glycoprotein South Africa variant antibody, STJ506305
ADDITIONAL INFORMATION	
Note	STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.